Michael Krams

发表

Barriers and opportunities for implementation of adaptive designs in pharmaceutical product development

Judith Quinlan, Brenda Gaydos, Jeff Maca, 2010, Clinical trials.

Considerations and Optimization of Adaptive Trial Design in Clinical Development Programs

Michael Krams, Vladimir Dragalin, M. Krams, 2014 .

A Bayesian Decision-Theoretic Dose-Finding Trial

Peter Müller, Michael Krams, Don A. Berry, 2006, Decis. Anal..

Adaptive Seamless Phase II/III Designs—Background, Operational Aspects, and Examples

Jeff Maca, Suman Bhattacharya, Michael Krams, 2006 .

Implementing Adaptive Designs: Logistical and Operational Considerations

Michael Krams, Judith Quinlan, M. Krams, 2006 .

Implementing Adaptive Designs: Using Technology to Protect Trial Integrity, Reduce Operational Bias, and Build Regulatory Trust

Michael Krams, Judith Quinlan, 2014 .

Adaptive Approaches in Clinical Drug Development

Amarnath Sharma, Michael Krams, Vlad Dragalin, 2012, Pharmaceutical Medicine.

A Case Study for Adaptive Trial Design Consideration and Implementation

Michael Krams, Vladimir Dragalin, M. Krams, 2014 .

A Bayesian Dose-Finding Design Adapting to Efficacy and Tolerability Response

Vladimir Dragalin, Michael Krams, Scott Berry, 2012, Journal of biopharmaceutical statistics.

Where the BOLD signal goes when alpha EEG leaves

Helmut Laufs, Joseph S. Paul, Michael Krams, 2006, NeuroImage.

Adaptive Bayesian Designs for Dose-Ranging Drug Trials

Michael D. Smith, Donald A. Berry, Michael Krams, 2002 .

Planning and Executing Response-Adaptive Learn-Phase Clinical Trials: 2. Case Studies

Amarnath Sharma, Kathy Reinold, Michael Krams, 2009 .

Adaptive Dose-Response Studies

Paul Gallo, Brenda Gaydos, Michael Krams, 2006 .

Data Monitoring in Adaptive Dose-Ranging Trials

Frank Bretz, Paul Gallo, Michael Krams, 2010 .

A Longitudinal Model for Non-Monotonic Clinical Assessment Scale Data

E. Niclas Jonsson, Scott Marshall, Michael Krams, 2005, Journal of Pharmacokinetics and Pharmacodynamics.

Planning and Executing Response-Adaptive Learn-Phase Clinical Trials: 1. The Process

Amarnath Sharma, Kathy Reinold, Michael Krams, 2009 .

Good Practices for Adaptive Clinical Trials in Pharmaceutical Product Development

Donald A. Berry, José Pinheiro, Christy Chuang-Stein, 2009 .

The past is the future: innovative designs in acute stroke therapy trials.

Michael Krams, Donald A Berry, Kennedy R Lees, 2005, Stroke.

UK-279,276, a Neutrophil Inhibitory Glycoprotein, in Acute Stroke: Tolerability and Pharmacokinetics

Michael Krams, Hans-Christoph Diener, H. Diener, 2003, Stroke.

PhRMA Working Group on Adaptive Designs: Introduction to the Full White Paper

Paul Gallo, Michael Krams, M. Krams, 2006 .

Cognitive Neuroscience NeuroReport

Karl J. Friston, John Ashburner, Michael Krams, 1999 .

ASTIN: a Bayesian adaptive dose–response trial in acute stroke

Andrew P Grieve, Michael Krams, M. Krams, 2005, Clinical trials.

Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): An Adaptive Dose-Response Study of UK-279,276 in Acute Ischemic Stroke

Andrew P Grieve, Michael Krams, Werner Hacke, 2003, Stroke.

A Bayesian dose-finding trial with adaptive dose expansion to flexibly assess efficacy and safety of an investigational drug

Michael Krams, Scott M Berry, Parvin Fardipour, 2010, Clinical trials.

Building a roadmap for developing combination therapies for Alzheimer’s disease

Steven Potkin, Michael Krams, Yaning Wang, 2015, Expert review of neurotherapeutics.

Simulation-based sequential Bayesian design

Donald A. Berry, Peter Müller, Michael Krams, 2007 .

Missing Steps in the STAIR Case: A Translational Medicine Perspective on the Development of NXY-059 for Treatment of Acute Ischemic Stroke

Michael Krams, Michael Poole, M. Krams, 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

Robotic Measurement of Arm Movements After Stroke Establishes Biomarkers of Motor Recovery

Hermano I Krebs, Michael Krams, Laura Dipietro, 2014, Stroke.

Effects of a Selective CD11b/CD18 Antagonist and Recombinant Human Tissue Plasminogen Activator Treatment Alone and in Combination in a Rat Embolic Model of Stroke

Michael Chopp, Li Zhang, Michael Krams, 2003, Stroke.

Evaluation of structural models to describe the effect of placebo upon the time course of major depressive disorder

Michael Krams, N. G. Denman, Diane R. Mould, 2009, Journal of Pharmacokinetics and Pharmacodynamics.

Recovery Robotic Measurement of Arm Movements After Stroke Establishes Biomarkers of Motor

Dimitris K. Agrafiotis, Bruce T. Volpe, Michael Krams, 2013 .

Adaptive platform trials: definition, design, conduct and reporting considerations

Herman Goossens, Donald A. Berry, Lorenzo Trippa, 2019, Nature Reviews Drug Discovery.

Charting a path toward combination therapy for Alzheimer’s disease

Michael Krams, Stephen Salloway, David Dilts, 2015, Expert review of neurotherapeutics.